Stock 300434 SICHUAN GOLDSTONE ASIA PHARMACEUTICAL INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Sichuan Goldstone Asia Pharmaceutical Inc.

Equities

300434

CNE100001YX5

End-of-day quote Shenzhen S.E.
Other stock markets
 18:00:00 2024-05-13 EDT 		5-day change 1st Jan Change
9.18 CNY +1.55% Intraday chart for Sichuan Goldstone Asia Pharmaceutical Inc. -1.82% -17.00%
04-25 Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
2023 Hangzhou Solipharma Technology Development Co., Ltd. announced that it expects to receive CNY 69.4857 million in funding from Sichuan Goldstone Asia Pharmaceutical Inc., Hangzhou Huolongguo Investment Management Co., Ltd. and another investor CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sichuan Goldstone Asia Pharmaceutical Inc. Proposes Final Cash Dividend for 2023
CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Hangzhou Solipharma Technology Development Co., Ltd. announced that it expects to receive CNY 69.4857 million in funding from Sichuan Goldstone Asia Pharmaceutical Inc., Hangzhou Huolongguo Investment Management Co., Ltd. and another investor
CI
Sichuan Goldstone Asia Pharmaceutical Inc. Approves Management Appointments
CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Sichuan Goldstone Asia Pharmaceutical Inc.(XSEC:300434) added to S&P Global BMI Index
CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Nine Months Ended September 30, 2021
CI
Gao Yaping completed the acquisition of 5.1% shares of Sichuan Goldstone Asia Pharmaceutical Inc. from Kuai Yixi and Yang Xiaodong.
CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Half Year Ended June 30, 2021
CI
Gao Yaping signed an equity transfer agreement to acquire 5.1% shares of Sichuan Goldstone Asia Pharmaceutical Inc. from Kuai Yixi and Yang Xiaodong for approximately CNY 170 million.
CI
Sichuan Goldstone Orient New Material Equipment Co., Ltd. Approves Final Cash Dividend for the Year 2020
CI
Sichuan Goldstone Asia Pharmaceutical Inc. signed Equity Acquisition agreement to acquire 65.40% stake in Zhejiang Jiande Zhengfa Pharmaceutical Co.Ltd from group of shareholders for approximately CNY 150 million
CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021
CI
Sichuan Goldstone Asia Pharmaceutical Inc. Reports Earnings Results for the Full Year Ended December 31, 2020
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 300434 Stock
  4. News Sichuan Goldstone Asia Pharmaceutical Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW